GSK's Arexvy Gets the Green Light in Europe: First-Ever RSV Vaccine in Europe for Older Adults
Portfolio Pulse from Vandana Singh
The European Commission has approved GSK's Arexvy, the first-ever RSV vaccine for older adults in Europe. The vaccine aims to prevent lower respiratory tract disease caused by RSV in adults aged 60 and older. The first launches are planned for the 2023/2024 RSV season. GSK and Pfizer are competing to tap into the RSV vaccine market, estimated to be worth over $5 billion and potentially exceeding $10 billion by 2030.
June 07, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer is competing with GSK to tap into the RSV vaccine market, which is estimated to be worth over $5 billion and could exceed $10 billion by 2030.
While Pfizer is not directly mentioned in the context of the European approval of GSK's Arexvy vaccine, the company is competing with GSK in the RSV vaccine market. The market's potential growth and value could have an impact on Pfizer's future performance, but the current news does not directly affect Pfizer's stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
GSK's Arexvy vaccine has been approved by the European Commission, marking the first RSV vaccine for older adults in Europe. The vaccine is set to launch in the 2023/2024 RSV season.
The approval of GSK's Arexvy vaccine in Europe is a significant milestone for the company, as it is the first RSV vaccine for older adults in the region. This approval will likely boost GSK's market position and revenue in the coming years, especially with the vaccine's planned launch in the 2023/2024 RSV season.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100